Maravai Lifesciences Holdings (MRVI) AI Stock Analysis

• Market Cap: $784.05M
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: -30.56%
• EPS Growth: 48.79%
• Country: US
• Employees: 570
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 146,383,160
• 10 Day Avg. Volume: 1,711,159
• 30 Day Avg. Volume: 1,327,240
• PEG Ratio: 0.27
• Price to Book (P/B): 2.22
• Price to Sales (P/S): 2.54
• P/FCF Ratio: -6.67
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 3.51
• Enterprise Value/Gross Profit: 19.50
• Enterprise Value/Ebitda: -4.43
• 1Y Price Target: $4.00
• Price Target Upside: 31.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -0.18
• Revenue Forecast (FY): $204.75M

• Rating: 53 Neutral
• Price Target: $3.00 ▼(-1.64% Downside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held back primarily by weak recent financial performance (steep revenue decline, large losses, and 2025 cash burn) despite improved leverage. Offsetting this, the latest earnings call provided comparatively strong turnaround signals (positive 2026 EBITDA outlook and sizable cost reductions) and the technical trend is moderately constructive with price above major moving averages.

Positive Factors

Nucleic-acid product commercial traction

Multiple new and platform products (ModTail, mRNAbuilder, IVT kits, GMP enzymes) have early repeat orders and bookings, indicating scalable commercial adoption. This product momentum supports a durable revenue base tied to growing nucleic-acid therapeutics demand if the company sustains execution and manufacturing capacity.

High-margin biologics testing franchise (Cygnus)

Cygnus delivers consistently high margins and positive adjusted EBITDA, providing a durable, cash-generative services franchise. Its steady growth and outsized profitability create internal cash flow that can support R&D and offset volatility in other segments, strengthening the firm's long-term financial flexibility.

Management execution: cost savings, guidance, and debt reduction

Leadership has delivered sizeable, sustained cost reductions and tangible balance-sheet action while guiding to meaningful 2026 profitability and cash-flow improvement. Exceeding $65M savings and voluntarily repaying debt are durable execution indicators that materially reduce structural interest burden and improve the path to self-funded growth.

Negative Factors

Multi-year revenue decline and margin compression

A sustained, steep revenue contraction and large gross-margin deterioration reduce scale economics and fixed-cost absorption. Persistently lower top-line and compressed margins make it harder to rebuild operating leverage, fund R&D or capex, and require prolonged recovery to restore durable profitability.

Weak operating cash flow and recent cash burn

Material negative operating and free cash flow reduce financial flexibility and increase reliance on external financing or asset sales. Even with noncash charges and announced savings, persistent cash burn limits runway for reinvestment and raises execution risk until positive, repeatable cash generation is achieved.

Order lumpiness and program-driven revenue volatility

Structural lumpiness tied to customer program timing undermines revenue visibility and complicates capacity planning, working-capital management, and forecasting. That persistent volatility elevates execution risk and can amplify cash-flow swings even as underlying demand slowly recovers.

Maravai Lifesciences Holdings Business Overview & Revenue Model

Company Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

How the Company Makes Money

Maravai makes money by selling consumables, custom-manufactured materials, and contracted services to pharmaceutical/biotechnology companies, diagnostic developers, and research customers. Key revenue streams include: 1) Nucleic Acid Production and Enabling Technologies: The company generates revenue from supplying critical nucleic acid components and related services used to develop and manufacture RNA-based medicines and vaccines and other advanced therapies. This includes custom and catalog products (e.g., specialty reagents and components used in nucleic-acid workflows) as well as contract manufacturing/services for customers that need materials produced to specific requirements. Revenue in this area typically scales with customer R&D activity, clinical progression, and commercial manufacturing demand. 2) Biologics Safety Testing Services: Through its testing operations, Maravai earns service revenue by performing contamination and quality-control testing for biologics manufacturing (e.g., assays used to help ensure product safety during development and production). These services are generally sold on a fee-for-service basis and are tied to customers’ development programs and manufacturing volumes. 3) Protein Detection and Research Tools: Maravai also sells research-use products used to detect, quantify, or characterize proteins in laboratory workflows. This business earns revenue from product sales to academic, government, and industry laboratories, typically as repeat consumable/tool purchases. Across these streams, earnings are influenced by demand for bioprocessing and advanced-therapy inputs, the pace of customers’ clinical and commercial milestones, and broader funding and spending levels in biotech and life science research. Specific significant partnerships or customer concentration details: null.

Maravai Lifesciences Holdings Financial Statement Overview

Summary

Overall fundamentals are pressured: revenue has contracted sharply (including ~74% drop in 2025 vs 2024), margins compressed materially, and profitability remains deeply negative with negative operating and free cash flow in 2025. A notable offset is the improved leverage profile from the sharp reduction in debt in 2025, but shrinking equity and continued losses keep financial risk elevated.

Income Statement

The income statement shows a sharp deterioration in scale and profitability. Revenue fell materially in 2025 versus 2024 (down ~74%), following declines in 2023 and 2024, signaling a multi-year contraction. Margins also weakened: gross margin compressed to ~26% in 2025 from ~42% in 2024 and ~81–82% in 2021–2022. Profitability is deeply negative, with a very large net loss in 2025 (net margin roughly -262%), indicating significant costs and/or charges relative to the reduced revenue base. The key strength is historical profitability in 2020–2022, but the most recent two years show substantial pressure and volatility.

Balance Sheet

The balance sheet looks mixed but has recently improved on leverage. Total debt dropped sharply in 2025 to ~$36M from ~$377M in 2024, bringing debt-to-equity down to ~0.17x (from ~1.16x in 2024 and ~1.47x in 2023), which reduces financial risk. However, equity declined from ~$325M (2024) to ~$212M (2025), and returns on equity are meaningfully negative in 2023–2025, consistent with ongoing net losses and pressure on book value. Overall: stronger leverage profile in the latest year, but weakened shareholder returns and shrinking capital base are clear offsets.

Cash Flow

Cash flow trends have turned negative and less dependable. Operating cash flow swung from positive in 2023 (~$126M) to slightly positive in 2024 (~$7M) and then materially negative in 2025 (~-$58M), indicating the business is consuming cash in operations. Free cash flow also deteriorated from strongly positive in 2022–2023 to negative in 2024 and 2025 (about -$71M in 2025). A positive point is that free cash flow was less negative than net income in 2025 (free cash flow to net income > 1), implying non-cash losses are significant, but the core issue remains: recent cash burn and weaker cash generation compared with earlier years.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	185.74M	259.19M	288.94M	883.00M	799.24M
Gross Profit	33.39M	108.31M	140.20M	714.04M	658.68M
EBITDA	-147.11M	-156.92M	712.41M	609.99M	585.78M
Net Income	-130.77M	-144.85M	-119.03M	220.21M	182.04M
Balance Sheet
Total Assets	770.58M	1.01B	1.49B	2.28B	1.92B
Cash, Cash Equivalents and Short-Term Investments	216.89M	322.40M	574.96M	632.14M	551.27M
Total Debt	35.58M	376.69M	610.97M	585.26M	575.22M
Total Liabilities	397.87M	431.04M	697.57M	1.38B	1.37B
Stockholders Equity	212.38M	325.29M	416.75M	545.22M	315.50M
Cash Flow
Free Cash Flow	-70.72M	-22.19M	60.67M	518.89M	353.72M
Operating Cash Flow	-57.57M	7.46M	126.22M	535.98M	368.57M
Investing Cash Flow	-31.41M	-24.32M	-122.31M	-267.61M	105.66M
Financing Cash Flow	-16.50M	-235.71M	-61.09M	-187.50M	-159.05M

Maravai Lifesciences Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Negative. The current price of 3.05 is below the 20-day moving average (MA) of 3.37, below the 50-day MA of 3.45, and above the 200-day MA of 3.02, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 38.58 is Neutral, neither overbought nor oversold. The STOCH value of 13.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRVI.

Maravai Lifesciences Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLAY	59 Neutral	$1.77B	-5.25	-43.17%	―	-16.50%	33.02%
MRVI	53 Neutral	$784.05M	-3.61	-51.07%	―	-30.56%	48.79%
KURA	52 Neutral	$741.09M	-3.27	-102.59%	―	―	-5.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMTX	51 Neutral	$1.30B	-5.79	-39.69%	―	-27.61%	-69.49%
GHRS	50 Neutral	$931.68M	-16.06	-16.30%	―	―	8.16%
IVA	47 Neutral	$1.22B	-0.42	536.36%	―	-12.52%	-82.84%